Ceftazidime: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
==US Brand Names== | ==US Brand Names== | ||
FORATZ<sup>®</sup>,TAZICEF<sup>®</sup>,CEFTAZIDIME<sup>®</sup>. | FORATZ<sup>®</sup>,TAZICEF<sup>®</sup>,CEFTAZIDIME<sup>®</sup>. | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
| Line 30: | Line 28: | ||
'''| [[Ceftazidime how supplied|How Supplied]]''' | '''| [[Ceftazidime how supplied|How Supplied]]''' | ||
'''| [[Ceftazidime labels and packages|Labels and Packages]]''' | '''| [[Ceftazidime labels and packages|Labels and Packages]]''' | ||
==Mechanism of action== | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 19:54, 26 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| Directions for use |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftazidime (INN) (IPA: Template:IPA) is a third-generationcephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negativebacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections.
Category
Cephalosporin, Third-Generation
US Brand Names
FORATZ®,TAZICEF®,CEFTAZIDIME®.
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages